Literature DB >> 24855481

Longitudinal surveillance of outpatient tetracycline, sulfonamide-trimethoprim and 'other' antimicrobial use in Canada, 1995 to 2010.

Shiona K Glass-Kaastra1, Rita Finley1, Jim Hutchinson2, David M Patrick3, Karl Weiss4, John Conly5.   

Abstract

INTRODUCTION: Monitoring the volume and patterns of use of antimicrobial agents is important in light of antimicrobial resistance.
OBJECTIVE: To assess the use of three antimicrobial groups - tetracycline, sulfonamide-trimethoprim and 'other' antimicrobials - within Canadian provinces over time.
METHODS: Prescription counts from 1995 to 2010 were acquired for the tetracycline and sulfonamide-trimethoprim groups of antimicrobials, and from 2001 to 2010 for the 'other' antimicrobial group. Linear mixed models were produced to assess differences among provinces and over time while accounting for repeated measurements. Prescription rate, defined daily dose per 1000 inhabitant-days and defined daily doses per prescription measures for the year 2009 were also compared with those reported by participating European Union countries to determine where Canadian provinces rank in terms of antimicrobial use among these countries.
RESULTS: Prescribing of all three groups varied according to province and over time. Tetracycline and sulfonamide-trimethoprim group prescribing were significantly reduced over the study period, by 36% and 61%, respectively. Prescribing of the 'other' antimicrobial group increased in all provinces from 2001 to 2010 with the exception of Prince Edward Island, although by varying amounts (10% to 61% increases). DISCUSSION: The overall use of antimicrobials in Canada has dropped from 1995 to 2010, and the tetracycline and sulfonamide-trimethoprim groups have contributed to this decline. The use of the 'other' antimicrobials has increased, however. These results may suggest that switches are being made among these groups, particularly among the antimicrobials used to treat urinary tract infections.

Entities:  

Keywords:  Antimicrobial use; Metronidazole; Prescribing patterns; Surveillance; Tetracycline

Year:  2014        PMID: 24855481      PMCID: PMC4028667          DOI: 10.1155/2014/248598

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  7 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

Review 2.  Management of acne.

Authors:  John Kraft; Anatoli Freiman
Journal:  CMAJ       Date:  2011-02-28       Impact factor: 8.262

3.  Change in antimicrobial susceptibility of Escherichia coli urinary tract isolates at a single institution over a period of 10 years.

Authors:  A Walkty; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; K Manickam; H Adam; P Pieroni; M Alfa
Journal:  Can J Microbiol       Date:  2012-02-27       Impact factor: 2.419

4.  Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited.

Authors:  Gunnar Kahlmeter; Hanna Odén Poulsen
Journal:  Int J Antimicrob Agents       Date:  2011-11-03       Impact factor: 5.283

5.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient use of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in Europe (1997-2009).

Authors:  Samuel Coenen; Niels Adriaenssens; Ann Versporten; Arno Muller; Girma Minalu; Christel Faes; Vanessa Vankerckhoven; Marc Aerts; Niel Hens; Geert Molenberghs; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2011-12       Impact factor: 5.790

6.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009).

Authors:  Niels Adriaenssens; Samuel Coenen; Ann Versporten; Arno Muller; Girma Minalu; Christel Faes; Vanessa Vankerckhoven; Marc Aerts; Niel Hens; Geert Molenberghs; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2011-12       Impact factor: 5.790

Review 7.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.